Parameswaran Hari, MD, MRCP

Chief, Professor

view physician profile

Locations

Froedtert Hospital
Cancer Center - Froedtert Hospital
Cancer Center - Moorland Reserve Health Center

Specialties

Hematology
Medical Oncology

Languages

Hindi, Urdu, Tamil, Malayalam, English

Contact Information

Education

MD - Doctor of Medicine
MRCP (U.K.) - Member Royal College of Physicians

Biography

Parameswaran Hari, MD, MRCP, MS, is the Armand J. Quick/William F. Stapp Professor of Hematology at Medical College of Wisconsin. Dr. Hari serves as Chief in the Division of Hematology and Oncology in the Department of Medicine. After medical school in India, he completed training in Internal Medicine and Hematology in the United Kingdom and then in Medical Oncology and Transplantation at the Medical College of Wisconsin.

Research Interests

His primary clinical interests are in cellular therapies and plasma cell disorders - multiple Myeloma, Amyloidosis and other monoclonal gammopathies. Dr. Hari is also Scientific Director of the plasma cell disorders working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR).

Propylene Glycol-Free Melphalan versus PG-Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation for Myeloma.

(Monahan K, Kleman A, Thapa B, Szabo A, D'Souza A, Dhakal B, Jerkins JH, Pasquini MC, Hamadani M, Hari PN, Chhabra S.) Biol Blood Marrow Transplant. 2020 Dec;26(12):2229-2236 PMID: 32920204 SCOPUS ID: 2-s2.0-85092250990 09/14/2020
Utilization and Cost Implications of Hematopoietic Progenitor Cells Stored for a Future Salvage Autologous Transplantation or Stem Cell Boost in Myeloma Patients.

(Chhabra S, Thapa B, Szabo A, Konings S, D'Souza A, Dhakal B, Jerkins JH, Pasquini MC, Johnson BD, Hari PN, Hamadani M.) Biol Blood Marrow Transplant. 2020 Nov;26(11):2011-2017 PMID: 32717431 SCOPUS ID: 2-s2.0-85090300711 07/28/2020
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.

(Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, Krueger W, Worden AA, Kadan MJ, Yim S, Cunningham A, Hamadani M, Fenske TS, Dropulić B, Orentas R, Hari P.) Nat Med. 2020 10;26(10):1569-1575 PMID: 33020647 SCOPUS ID: 2-s2.0-85092105030 10/07/2020
Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH.

(Cornell R, Hari P, Tang S, Biran N, Callander N, Chari A, Chhabra S, Fiala MA, Gahvari Z, Gandhi U, Godby K, Gupta R, Jagannath S, Jagosky M, Kang Y, Kansagra A, Kauffman M, Kodali S, Kumar SK, Lakshman A, Liedtke M, Lonial S, Ma X, Malek E, Mansour J, McGehee EF, Neppalli A, Paul B, Richardson P, Scott EC, Shacham S, Shah J, Siegel DS, Umyarova E, Usmani SZ, Varnado W, Vij R, Costa L.) Am J Hematol. 2020 Sep 24 PMID: 32974944 SCOPUS ID: 2-s2.0-85092920395 09/26/2020
African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States.

(Badar T, Hari P, Dávila O, Fraser R, Wirk B, Dhakal B, Freytes CO, Rodriguez Valdes C, Lee C, Vesole DH, Malek E, Hildebrandt GC, Landau H, Murthy HS, Lazarus HM, Berdeja JG, Meehan KR, Solh M, Diaz MA, Kharfan-Dabaja MA, Callander NS, Farhadfar N, Bashir Q, Kamble RT, Vij R, Munker R, Kyle RA, Chhabra S, Hashmi S, Ganguly S, Jagannath S, Nishihori T, Nieto Y, Kumar S, Shah N, D'Souza A.) Cancer. 2020 Sep 23 PMID: 32966625 SCOPUS ID: 2-s2.0-85091313309 09/24/2020
Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen.

(Hagen P, D'Souza A, Hari P, Davila O, Zhang MJ, Vesole DH, Smith SE, Rodriguez TE, Stiff PJ.) Leuk Lymphoma. 2020 Aug 31:1-9 PMID: 32865474 SCOPUS ID: 2-s2.0-85089967898 09/01/2020
Autonomic nervous system control of multiple myeloma.

(Cheng Y, Sun F, D'Souza A, Dhakal B, Pisano M, Chhabra S, Stolley M, Hari P, Janz S.) Blood Rev. 2020 Aug 11:100741 PMID: 32807576 SCOPUS ID: 2-s2.0-85089534779 08/19/2020
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.

(Costa LJ, Derman BA, Bal S, Sidana S, Chhabra S, Silbermann R, Ye JC, Cook G, Cornell RF, Holstein SA, Shi Q, Omel J, Callander NS, Chng WJ, Hungria V, Maiolino A, Stadtmauer E, Giralt S, Pasquini M, Jakubowiak AJ, Morgan GJ, Krishnan A, Jackson GH, Mohty M, Mateos MV, Dimopoulos MA, Facon T, Spencer A, Miguel JS, Hari P, Usmani SZ, Manier S, McCarthy P, Kumar S, Gay F, Paiva B.) Leukemia. 2020 Aug 11 PMID: 32778736 SCOPUS ID: 2-s2.0-85089253567 08/12/2020
Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges.

(Dhakal B, Hari PN, Usmani SZ, Hamadani M.) Bone Marrow Transplant. 2020 Aug 07 PMID: 32770147 SCOPUS ID: 2-s2.0-85089253834 08/10/2020
Salvage second transplantation in relapsed multiple myeloma.

(Dhakal B, D'Souza A, Kleman A, Chhabra S, Mohan M, Hari P.) Leukemia. 2020 Aug 04 PMID: 32747684 SCOPUS ID: 2-s2.0-85088870056 08/05/2020
Discovery and validation of surface N-glycoproteins in MM cell lines and patient samples uncovers immunotherapy targets.

(Oldham RAA, Faber ML, Keppel TR, Buchberger AR, Waas M, Hari P, Gundry RL, Medin JA.) J Immunother Cancer. 2020 Aug;8(2) PMID: 32771993 PMCID: PMC7418848 SCOPUS ID: 2-s2.0-85089262124 08/11/2020
Prevalence and significance of sarcopenia in multiple myeloma patients undergoing autologous hematopoietic cell transplantation.

(Williams A, Baruah D, Patel J, Szabo A, Chhabra S, Dhakal B, Hari P, Janz S, Stolley M, D'Souza A.) Bone Marrow Transplant. 2020 Jul 30 PMID: 32732941 SCOPUS ID: 2-s2.0-85088830942 08/01/2020